Antiangiogenic therapy induces cell hypoxia, which leads to downregulation of HR repair genes (BRCA1, BRCA2, and RAD51), increasing tumor sensitivity to PARPis (Bindra et al., 2005). Here, BRCA1 is linked to neoplasm.